On the public citation graph

PCSK9 Biology and Its Role in Atherothrombosis

https://doi.org/10.3390/ijms22115880
0 signed · 343 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2016.13985openalex-snapshot
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
inferredcites →https://doi.org/10.1001/jama.285.13.1711openalex-snapshot
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes The MIRACL Study: A Randomized Controlled Trial
inferredcites →https://doi.org/10.1001/jamacardio.2020.3151openalex-snapshot
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
inferredcites →https://doi.org/10.1002/cmdc.202000431openalex-snapshot
Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design
inferredcites →https://doi.org/10.1002/jca.21632openalex-snapshot
Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low‐density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report
inferredcites →https://doi.org/10.1002/pro.5560060301openalex-snapshot
Subtilases: The superfamily of subtilisin-like serine proteases
inferredcites →https://doi.org/10.1007/978-1-4684-5568-7_58openalex-snapshot
Is Oxidized Low Density Lipoprotein Involved in the Recruitment and Retention of Monocyte/Macrophages in the Artery Wall during the Initiation of Atherosclerosis?
inferredcites →https://doi.org/10.1007/s00018-003-2249-yopenalex-snapshot
Low-density lipoprotein and its effect on human blood platelets
inferredcites →https://doi.org/10.1007/s00109-007-0172-7openalex-snapshot
The proprotein convertases are potential targets in the treatment of dyslipidemia
inferredcites →https://doi.org/10.1007/s00439-003-1071-9openalex-snapshot
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
inferredcites →https://doi.org/10.1007/s11010-014-2259-0openalex-snapshot
Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages
inferredcites →https://doi.org/10.1007/s11883-014-0401-9openalex-snapshot
Pathophysiology of Acute Coronary Syndrome
inferredcites →https://doi.org/10.1007/s40265-021-01473-6openalex-snapshot
Inclisiran: First Approval
inferredcites →https://doi.org/10.1016/j.ajpath.2021.04.016openalex-snapshot
Proprotein Convertase Subtilisin/Kexin Type 9
inferredcites →https://doi.org/10.1016/j.arr.2018.09.004openalex-snapshot
Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2004.02.008openalex-snapshot
Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2005.02.016openalex-snapshot
Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2006.08.039openalex-snapshot
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2008.10.007openalex-snapshot
Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2009.02.006openalex-snapshot
Commentary PCSK9 variants: A new database
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2009.02.012openalex-snapshot
Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2011.04.018openalex-snapshot
Clinical aspects of PCSK9
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2011.11.026openalex-snapshot
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2013.01.023openalex-snapshot
PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2015.09.008openalex-snapshot
A systematic literature review of the effect of carotid atherosclerosis on local vessel stiffness and elasticity
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2016.08.007openalex-snapshot
PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2018.06.871openalex-snapshot
Lipid management in ACS: Should we go lower faster?
inferredcites →https://doi.org/10.1016/j.atherosclerosis.2018.07.014openalex-snapshot
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
inferredcites →https://doi.org/10.1016/j.bbadis.2014.05.009openalex-snapshot
Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis
inferredcites →https://doi.org/10.1016/j.bbrc.2008.07.106openalex-snapshot
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
inferredcites →https://doi.org/10.1016/j.biopha.2018.09.164openalex-snapshot
No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia
inferredcites →https://doi.org/10.1016/j.cca.2014.01.043openalex-snapshot
PCSK9 gene mutations and low-density lipoprotein cholesterol
inferredcites →https://doi.org/10.1016/j.celrep.2015.11.006openalex-snapshot
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
inferredcites →https://doi.org/10.1016/j.diabet.2017.07.009openalex-snapshot
Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study
inferredcites →https://doi.org/10.1016/j.gheart.2018.09.511openalex-snapshot
Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control
inferredcites →https://doi.org/10.1016/j.ijcard.2016.04.103openalex-snapshot
Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
inferredcites →https://doi.org/10.1016/j.ijcard.2016.10.084openalex-snapshot
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
inferredcites →https://doi.org/10.1016/j.jacc.2007.02.059openalex-snapshot
Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling
inferredcites →https://doi.org/10.1016/j.jacc.2017.11.069openalex-snapshot
PCSK9 as a Positive Modulator of Platelet Activation
inferredcites →https://doi.org/10.1016/j.jacc.2018.11.003openalex-snapshot
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
inferredcites →https://doi.org/10.1016/j.jacc.2019.03.010openalex-snapshot
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
inferredcites →https://doi.org/10.1016/j.jacl.2011.03.001openalex-snapshot
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
inferredcites →https://doi.org/10.1016/j.jacl.2011.04.003openalex-snapshot
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
inferredcites →https://doi.org/10.1016/j.jacl.2017.09.003openalex-snapshot
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
inferredcites →https://doi.org/10.1016/j.jacl.2017.12.008openalex-snapshot
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
inferredcites →https://doi.org/10.1016/j.jacl.2018.02.004openalex-snapshot
Improved endothelial function after short-term therapy with evolocumab
inferredcites →https://doi.org/10.1016/j.mam.2004.09.003openalex-snapshot
The role of nitric oxide in cardiovascular diseases
inferredcites →https://doi.org/10.1016/j.numecd.2011.06.002openalex-snapshot
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition
inferredcites →https://doi.org/10.1016/j.numecd.2019.01.010openalex-snapshot
Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors
inferredcites →https://doi.org/10.1016/j.numecd.2019.09.012openalex-snapshot
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
inferredcites →https://doi.org/10.1016/j.numecd.2020.02.018openalex-snapshot
Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab®: A prospective cohort study
inferredcites →https://doi.org/10.1016/j.phrs.2019.03.021openalex-snapshot
Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials
inferredcites →https://doi.org/10.1016/j.plipres.2011.04.002openalex-snapshot
Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy
inferredcites →https://doi.org/10.1016/j.str.2007.04.004openalex-snapshot
The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol
inferredcites →https://doi.org/10.1016/j.thromres.2019.06.010openalex-snapshot
Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin
inferredcites →https://doi.org/10.1016/j.thromres.2020.07.049openalex-snapshot
Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy
inferredcites →https://doi.org/10.1016/j.tibs.2006.12.008openalex-snapshot
Molecular biology of PCSK9: its role in LDL metabolism
inferredcites →https://doi.org/10.1016/s0009-8981(02)00337-6openalex-snapshot
Elevated cell-free serum DNA detected in patients with myocardial infarction
inferredcites →https://doi.org/10.1016/s0140-6736(10)61350-5openalex-snapshot
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
inferredcites →https://doi.org/10.1016/s0140-6736(12)60367-5openalex-snapshot
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
inferredcites →https://doi.org/10.1016/s2213-8587(17)30313-3openalex-snapshot
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
inferredcites →https://doi.org/10.1016/s2213-8587(19)30388-2openalex-snapshot
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
inferredcites →https://doi.org/10.1038/labinvest.2017.47openalex-snapshot
Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation
inferredcites →https://doi.org/10.1038/nature08938openalex-snapshot
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
inferredcites →https://doi.org/10.1038/ng1161openalex-snapshot
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
inferredcites →https://doi.org/10.1038/ng1509openalex-snapshot
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
inferredcites →https://doi.org/10.1038/nm.2053openalex-snapshot
Extracellular histones are major mediators of death in sepsis
inferredcites →https://doi.org/10.1038/nm1626openalex-snapshot
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
inferredcites →https://doi.org/10.1038/nrd3699openalex-snapshot
The biology and therapeutic targeting of the proprotein convertases
inferredcites →https://doi.org/10.1038/oby.2009.302openalex-snapshot
In Central Obesity, Weight Loss Restores Platelet Sensitivity to Nitric Oxide and Prostacyclin
inferredcites →https://doi.org/10.1038/s41569-018-0098-5openalex-snapshot
Safety and efficacy of statin therapy
inferredcites →https://doi.org/10.1038/s41569-018-0110-0openalex-snapshot
Platelet biology and functions: new concepts and clinical perspectives
inferredcites →https://doi.org/10.1038/s41586-021-03534-yopenalex-snapshot
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
inferredcites →https://doi.org/10.1038/s41587-021-00933-4openalex-snapshot
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
inferredcites →https://doi.org/10.1038/s41598-017-14307-xopenalex-snapshot
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
inferredcites →https://doi.org/10.1038/s41598-018-20425-xopenalex-snapshot
PCSK9 induces a pro-inflammatory response in macrophages
inferredcites →https://doi.org/10.1056/nejm199705013361802openalex-snapshot
Coronary Risk Factors and Plaque Morphology in Men with Coronary Disease Who Died Suddenly
inferredcites →https://doi.org/10.1056/nejmc1509363openalex-snapshot
Ezetimibe plus a Statin after Acute Coronary Syndromes
inferredcites →https://doi.org/10.1056/nejmoa054013openalex-snapshot
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
inferredcites →https://doi.org/10.1056/nejmoa1609243openalex-snapshot
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
inferredcites →https://doi.org/10.1056/nejmoa1615664openalex-snapshot
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
inferredcites →https://doi.org/10.1056/nejmoa1801174openalex-snapshot
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
inferredcites →https://doi.org/10.1056/nejmoa1816454openalex-snapshot
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
inferredcites →https://doi.org/10.1056/nejmoa1913805openalex-snapshot
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
inferredcites →https://doi.org/10.1073/pnas.0335507100openalex-snapshot
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation
inferredcites →https://doi.org/10.1073/pnas.0402133101openalex-snapshot
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
inferredcites →https://doi.org/10.1073/pnas.0409736102openalex-snapshot
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
inferredcites →https://doi.org/10.1073/pnas.0501652102openalex-snapshot
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
inferredcites →https://doi.org/10.1073/pnas.0712064105openalex-snapshot
Molecular basis for LDL receptor recognition by PCSK9
inferredcites →https://doi.org/10.1073/pnas.1005743107openalex-snapshot
Extracellular DNA traps promote thrombosis
inferredcites →https://doi.org/10.1074/jbc.c700095200openalex-snapshot
Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells
inferredcites →https://doi.org/10.1074/jbc.m109.037085openalex-snapshot
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
inferredcites →https://doi.org/10.1074/jbc.m112.380618openalex-snapshot
Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
inferredcites →https://doi.org/10.1074/jbc.m112.421370openalex-snapshot
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
inferredcites →https://doi.org/10.1074/jbc.m115.638361openalex-snapshot
K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells
inferredcites →https://doi.org/10.1074/jbc.m409699200openalex-snapshot
NARC-1/PCSK9 and Its Natural Mutants
inferredcites →https://doi.org/10.1074/jbc.m410077200openalex-snapshot
Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver
inferredcites →https://doi.org/10.1074/jbc.m606495200openalex-snapshot
The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A
inferredcites →https://doi.org/10.1074/jbc.m708098200openalex-snapshot
The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2
inferredcites →https://doi.org/10.1080/09537109709169333openalex-snapshot
Differential effects of native and oxidatively modified low-density lipoproteins on platelet function
inferredcites →https://doi.org/10.1080/13543784.2018.1442435openalex-snapshot
Inclisiran for the treatment of dyslipidemia
inferredcites →https://doi.org/10.1084/jem.20112322openalex-snapshot
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
inferredcites →https://doi.org/10.1086/507488openalex-snapshot
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote
inferredcites →https://doi.org/10.1089/ars.2014.6054openalex-snapshot
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
inferredcites →https://doi.org/10.1089/ars.2016.6631openalex-snapshot
Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis
inferredcites →https://doi.org/10.1093/cvr/cvv178openalex-snapshot
Cross-talk between LOX-1 and PCSK9 in vascular tissues
inferredcites →https://doi.org/10.1093/cvr/cvw053openalex-snapshot
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
inferredcites →https://doi.org/10.1093/cvr/cvy079openalex-snapshot
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
inferredcites →https://doi.org/10.1093/cvr/cvz262openalex-snapshot
Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines
inferredcites →https://doi.org/10.1093/eurheartj/ehx144openalex-snapshot
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
inferredcites →https://doi.org/10.1093/eurheartj/ehz455openalex-snapshot
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
inferredcites →https://doi.org/10.1093/eurheartj/ehz566openalex-snapshot
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
inferredcites →https://doi.org/10.1093/nar/gkp971openalex-snapshot
MEROPS: the peptidase database
inferredcites →https://doi.org/10.1097/shk.0000000000000397openalex-snapshot
Comparison of the Proinflammatory and Procoagulant Properties of Nuclear, Mitochondrial, and Bacterial DNA
inferredcites →https://doi.org/10.1097/shk.0000000000000682openalex-snapshot
Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis
inferredcites →https://doi.org/10.1097/shk.0b013e31816a6bb1openalex-snapshot
NEUTROPHIL-DERIVED CIRCULATING FREE DNA (cf-DNA/NETs)
inferredcites →https://doi.org/10.1111/j.0009-9163.2004.0238.xopenalex-snapshot
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
inferredcites →https://doi.org/10.1111/j.1365-2796.2009.02167.xopenalex-snapshot
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
inferredcites →https://doi.org/10.1111/j.1538-7836.2008.03267.xopenalex-snapshot
Platelet count and the risk for thrombosis and death in the elderly
inferredcites →https://doi.org/10.1111/j.1538-7836.2011.04465.xopenalex-snapshot
Breast cancer chemotherapy induces the release of cell‐free DNA, a novel procoagulant stimulus
inferredcites →https://doi.org/10.1111/j.1742-4658.2011.08219.xopenalex-snapshot
Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low‐density lipoprotein receptors on HepG2 cells
inferredcites →https://doi.org/10.1126/science.1092385openalex-snapshot
Neutrophil Extracellular Traps Kill Bacteria
inferredcites →https://doi.org/10.1126/science.1205677openalex-snapshot
A Key Enzyme in the Biogenesis of Lysosomes Is a Protease That Regulates Cholesterol Metabolism
inferredcites →https://doi.org/10.1126/scitranslmed.3008782openalex-snapshot
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
inferredcites →https://doi.org/10.1152/japplphysiol.00879.2009openalex-snapshot
EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling
inferredcites →https://doi.org/10.1155/2018/6508709openalex-snapshot
Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia
inferredcites →https://doi.org/10.1161/01.atv.0000193622.77294.57openalex-snapshot
Platelet Nitric Oxide Responsiveness
inferredcites →https://doi.org/10.1161/01.atv.0000249641.96896.e6openalex-snapshot
Macrophage Low-Density Lipoprotein Receptor-Related Protein Deficiency Enhances Atherosclerosis in ApoE/LDLR Double Knockout Mice
inferredcites →https://doi.org/10.1161/01.atv.0000259359.52265.62openalex-snapshot
Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis
inferredcites →https://doi.org/10.1161/01.cir.0000136032.40666.3dopenalex-snapshot
Aggregated Low-Density Lipoprotein Uptake Induces Membrane Tissue Factor Procoagulant Activity and Microparticle Release in Human Vascular Smooth Muscle Cells
inferredcites →https://doi.org/10.1161/01.cir.84.2.613openalex-snapshot
Blood platelet count and function are related to total and cardiovascular death in apparently healthy men.
inferredcites →https://doi.org/10.1161/01.cir.97.21.2110openalex-snapshot
Effect of Risk Factors on the Mechanism of Acute Thrombosis and Sudden Coronary Death in Women
inferredcites →https://doi.org/10.1161/atvbaha.110.210252openalex-snapshot
Deletion of the High-Density Lipoprotein Receptor Scavenger Receptor BI in Mice Modulates Thrombosis Susceptibility and Indirectly Affects Platelet Function by Elevation of Plasma Free Cholesterol
inferredcites →https://doi.org/10.1161/atvbaha.110.220988openalex-snapshot
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
inferredcites →https://doi.org/10.1161/atvbaha.111.242859openalex-snapshot
Neutrophil Extracellular Trap (NET) Impact on Deep Vein Thrombosis
inferredcites →https://doi.org/10.1161/atvbaha.112.250043openalex-snapshot
Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
inferredcites →https://doi.org/10.1161/atvbaha.114.304114openalex-snapshot
Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms
inferredcites →https://doi.org/10.1161/atvbaha.114.304406openalex-snapshot
PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia
inferredcites →https://doi.org/10.1161/atvbaha.115.306035openalex-snapshot
Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis
inferredcites →https://doi.org/10.1161/circresaha.114.301621openalex-snapshot
PCSK9
inferredcites →https://doi.org/10.1161/circresaha.114.302721openalex-snapshot
Mechanisms of Plaque Formation and Rupture
inferredcites →https://doi.org/10.1161/circresaha.114.302937openalex-snapshot
Induction of Atherosclerosis in Mice and Hamsters Without Germline Genetic Engineering
inferredcites →https://doi.org/10.1161/circresaha.117.310795openalex-snapshot
Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis
inferredcites →https://doi.org/10.1161/circresaha.118.311362openalex-snapshot
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
inferredcites →https://doi.org/10.1161/circulationaha.111.057406openalex-snapshot
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
inferredcites →https://doi.org/10.1161/circulationaha.113.001592openalex-snapshot
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
inferredcites →https://doi.org/10.1161/circulationaha.113.006720openalex-snapshot
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
inferredcites →https://doi.org/10.1161/circulationaha.115.018531openalex-snapshot
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
inferredcites →https://doi.org/10.1161/circulationaha.119.043805openalex-snapshot
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
inferredcites →https://doi.org/10.1161/circulationaha.119.044434openalex-snapshot
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial
inferredcites →https://doi.org/10.1161/circulationaha.120.046290openalex-snapshot
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
inferredcites →https://doi.org/10.1161/circulationaha.120.046397openalex-snapshot
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
inferredcites →https://doi.org/10.1161/strokeaha.119.027759openalex-snapshot
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
inferredcites →https://doi.org/10.1177/2047487319839179openalex-snapshot
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk
inferredcites →https://doi.org/10.1182/blood-2013-04-457671openalex-snapshot
NETosis: how vital is it?
inferredcites →https://doi.org/10.1186/1471-2164-12-618openalex-snapshot
Identification of proprotein convertase substrates using genome-wide expression correlation analysis
inferredcites →https://doi.org/10.1194/jlr.m051326openalex-snapshot
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
inferredcites →https://doi.org/10.1194/jlr.m078360openalex-snapshot
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
inferredcites →https://doi.org/10.1194/jlr.r800091-jlr200openalex-snapshot
PCSK9: a convertase that coordinates LDL catabolism
inferredcites →https://doi.org/10.1253/circj.cj-15-0999openalex-snapshot
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
inferredcites →https://doi.org/10.1371/journal.pone.0064145openalex-snapshot
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
inferredcites →https://doi.org/10.1371/journal.pone.0157230openalex-snapshot
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
inferredcites →https://doi.org/10.1515/bmc.2011.034openalex-snapshot
On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications
inferredcites →https://doi.org/10.2147/ppa.s149423openalex-snapshot
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
inferredcites →https://doi.org/10.2459/jcm.0000000000000611openalex-snapshot
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients
inferredcites →https://doi.org/10.3390/antiox9040296openalex-snapshot
PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
inferredcites →https://doi.org/10.3390/ijms21020623openalex-snapshot
Influence of Cardiometabolic Risk Factors on Platelet Function
inferredcites →https://doi.org/10.3892/mmr.2017.6803openalex-snapshot
Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
inferredcites →https://doi.org/10.5551/jat.25841openalex-snapshot
The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
inferredcites →https://doi.org/10.5551/jat.27615openalex-snapshot
PCSK9: A key factor modulating atherosclerosis
inferredcites →https://doi.org/10.5551/jat.rv17003openalex-snapshot
PCSK9 and Atherosclerosis - Lipids and Beyond
inferredcites →https://doi.org/10.7326/0003-4819-158-4-201302190-00006openalex-snapshot
Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4760648openalex-extracted
Cholesterol Metabolism-Mediated Immune Regulation and Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/advs.202504291openalex-snapshot
PCSK9 Loss‐of‐Function Disrupts Cellular Microfilament Network via LIN28A/HES5/JMY Axis in Neural Tube Defects
inferred← citeshttps://doi.org/10.1002/ddr.70231openalex-snapshot
Targeting of PCSK9 in the Management of Alzheimer's Disease: Expanding the New Potential Key Player
inferred← citeshttps://doi.org/10.1002/ddr.70352openalex-snapshot
Discovery of Novel PCSK9‐LDLR PPI Inhibitors by a Structural Modification Approach
inferred← citeshttps://doi.org/10.1002/mco2.481openalex-snapshot
Drug development advances in human genetics‐based targets
inferred← citeshttps://doi.org/10.1002/ptr.8151openalex-snapshot
Therapeutic effects and molecular mechanisms of natural products in thrombosis
inferred← citeshttps://doi.org/10.1007/978-1-0716-3754-8_2openalex-snapshot
Immune Homeostasis Maintenance Through Advanced Immune Therapeutics to Target Atherosclerosis
inferred← citeshttps://doi.org/10.1007/978-981-95-9789-5_16openalex-snapshot
Single-Cell Analysis in Pharmacological Research for Blood Lipid Disorders
inferred← citeshttps://doi.org/10.1007/s00109-023-02336-1openalex-snapshot
Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy
inferred← citeshttps://doi.org/10.1007/s00203-025-04632-5openalex-snapshot
The role of low-density lipoprotein receptors in emerging and reemerging viruses: a review with examples from human metapneumovirus and beyond
inferred← citeshttps://doi.org/10.1007/s00203-026-05006-1openalex-snapshot
Review: natural compounds as PCSK9 inhibitors for antiviral therapy
inferred← citeshttps://doi.org/10.1007/s11033-022-07433-xopenalex-snapshot
A novel prothrombotic role of proprotein convertase subtilisin kexin 9: the generation of procoagulant extracellular vesicles by human mononuclear cells
inferred← citeshttps://doi.org/10.1007/s11255-025-04776-9openalex-snapshot
Serum PCSK9 level as a potential biomarker relating to age, cholesterol and predicting major adverse cardiovascular event risk in hemodialysis patients
inferred← citeshttps://doi.org/10.1007/s12265-022-10311-3openalex-snapshot
Advances in Glycolysis Metabolism of Atherosclerosis
inferred← citeshttps://doi.org/10.1007/s13105-024-01058-3openalex-snapshot
Histone demethylase JMJD1C advances macrophage foam cell formation and atherosclerosis progression by promoting the transcription of PCSK9
inferred← citeshttps://doi.org/10.1007/s40265-026-02348-4openalex-snapshot
Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering
inferred← citeshttps://doi.org/10.1007/s43032-025-01974-9openalex-snapshot
A High-Fat Diet Damages the Blood-Testis Barrier Through the PCSK9-LOX1 Positive Feedback Loop in Sertoli Cells
inferred← citeshttps://doi.org/10.1016/j.arcmed.2024.103032openalex-snapshot
Metabolic Changes Induced by Bariatric Surgery May be Mediated by PAI-1 and PCSK9 Crosstalk
inferred← citeshttps://doi.org/10.1016/j.artere.2025.100739openalex-snapshot
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs
inferred← citeshttps://doi.org/10.1016/j.arteri.2024.07.004openalex-snapshot
Nuevos fármacos para tratar las dislipemias. De las pequeñas moléculas a los ARN pequeños de interferencia
inferred← citeshttps://doi.org/10.1016/j.cca.2022.11.018openalex-snapshot
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
inferred← citeshttps://doi.org/10.1016/j.cellsig.2025.112044openalex-snapshot
Targeting SREBP2 in cancer progression: Molecular mechanisms, oncogenic crosstalk, and therapeutic interventions
inferred← citeshttps://doi.org/10.1016/j.celrep.2024.114285openalex-snapshot
Cholesterol reduction by immunization with a PCSK9 mimic
inferred← citeshttps://doi.org/10.1016/j.cpcardiol.2024.102419openalex-snapshot
Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials
inferred← citeshttps://doi.org/10.1016/j.ecl.2022.02.009openalex-snapshot
Lipoprotein Assessment in the twenty-first Century
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.116063openalex-snapshot
Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability
inferred← citeshttps://doi.org/10.1016/j.ejphar.2024.176352openalex-snapshot
Curcumin nicotinate increases LDL cholesterol uptake in hepatocytes through IDOL/LDL-R pathway regulation
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.177944openalex-snapshot
Urinary trypsin inhibitor exerts multifaceted regulation of angiopoietin 2 in septic cardiomyopathy
inferred← citeshttps://doi.org/10.1016/j.engreg.2025.07.002openalex-snapshot
The microenvironment in atherosclerosis: molecular regulation mechanism and immunotherapy
inferred← citeshttps://doi.org/10.1016/j.gendis.2023.101122openalex-snapshot
The role of lipid metabolism in osteoporosis: Clinical implication and cellular mechanism
inferred← citeshttps://doi.org/10.1016/j.gendis.2026.102435openalex-snapshot
Novel candidate targets for atherosclerosis: Insights from multi-omics approaches and clinical relevance
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.140381openalex-snapshot
Anti-hypercholesterolemic effects of small-molecule pectin from Premna ligustroides Hemsl leaves: Modulation of inflammatory markers and gut microbiota in mice
inferred← citeshttps://doi.org/10.1016/j.isci.2022.104670openalex-snapshot
Increased LDL receptor by SREBP2 or SREBP2-induced lncRNA LDLR-AS promotes triglyceride accumulation in fish
inferred← citeshttps://doi.org/10.1016/j.jacc.2026.06.026openalex-snapshot
Genetically Mediated Differences in LDL Cholesterol and Risk of Venous Thromboembolism
inferred← citeshttps://doi.org/10.1016/j.jare.2025.11.044openalex-snapshot
Identification and evaluation of a lipid-lowering small compound as a PCSK9 inhibitor
inferred← citeshttps://doi.org/10.1016/j.jaut.2022.102815openalex-snapshot
Lipoprotein oxidation may underlie the paradoxical association of low cholesterol with coronary atherosclerotic risk in rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/j.jlr.2024.100497openalex-snapshot
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
inferred← citeshttps://doi.org/10.1016/j.jrras.2025.101883openalex-snapshot
Therapeutic potential of astragalus polysaccharides in coronary heart disease: Insights into PCSK9/LDLR-mediated myocardial fibrosis
inferred← citeshttps://doi.org/10.1016/j.lpmfor.2024.01.014openalex-snapshot
Place des inhibiteurs du PCSK9 dans le traitement des hypercholestérolémies
inferred← citeshttps://doi.org/10.1016/j.metabol.2024.156064openalex-snapshot
PCSK9 in metabolism and diseases
inferred← citeshttps://doi.org/10.1016/j.numecd.2023.08.010openalex-snapshot
New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing
inferred← citeshttps://doi.org/10.1016/j.numecd.2024.04.007openalex-snapshot
Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.tibs.2021.12.005openalex-snapshot
Structural advances in sterol-sensing domain-containing proteins
inferred← citeshttps://doi.org/10.1016/j.toxrep.2023.09.016openalex-snapshot
Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
inferred← citeshttps://doi.org/10.1016/j.vph.2023.107170openalex-snapshot
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice
inferred← citeshttps://doi.org/10.1016/j.yjmcc.2022.08.348openalex-snapshot
Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01290openalex-snapshot
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
inferred← citeshttps://doi.org/10.1021/acsomega.3c00443openalex-snapshot
Imine Derivatives of Benzoxazole Attenuate High-Fat Diet-Induced Hyperlipidemia by Modulation of Lipid-Regulating Genes
inferred← citeshttps://doi.org/10.1021/acsomega.6c02002openalex-snapshot
Phenolic Compounds with PCSK9 Secretion Inhibitory Activities from the Fruits of Liriope spicata
inferred← citeshttps://doi.org/10.1021/prechem.5c00107openalex-snapshot
Efficient Synthesis of Enlicitide Chloride through Convergent Solution-Phase and Hybrid Solution–Solid-Phase Strategies
inferred← citeshttps://doi.org/10.1038/s41392-022-00955-7openalex-snapshot
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
inferred← citeshttps://doi.org/10.1038/s41401-024-01305-9openalex-snapshot
A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis
inferred← citeshttps://doi.org/10.1038/s41598-025-01677-wopenalex-snapshot
Quantitative proteomic analysis of the protective effect exerted by alliin on ox-LDL-injured HUVECs
inferred← citeshttps://doi.org/10.1038/s41598-025-03419-4openalex-snapshot
The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
inferred← citeshttps://doi.org/10.1038/s41598-025-12432-6openalex-snapshot
Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins
inferred← citeshttps://doi.org/10.1039/d2fo01711copenalex-snapshot
Effects of medium chain triglycerides on lipid metabolism in high-fat diet induced obese rats
inferred← citeshttps://doi.org/10.1055/a-2156-7872openalex-snapshot
Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial
inferred← citeshttps://doi.org/10.1055/s-0042-1758654openalex-snapshot
Drug–Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)
inferred← citeshttps://doi.org/10.1080/10408398.2022.2121261openalex-snapshot
Kaempferol and atherosclerosis: From mechanism to medicine
inferred← citeshttps://doi.org/10.1080/14740338.2025.2468855openalex-snapshot
Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)
inferred← citeshttps://doi.org/10.1080/14756366.2025.2610849openalex-snapshot
Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation
inferred← citeshttps://doi.org/10.1080/14796678.2024.2367860openalex-snapshot
Emerging therapies for refractory hypercholesterolemia: a narrative review
inferred← citeshttps://doi.org/10.1080/19475411.2024.2395270openalex-snapshot
Therapeutic potentials of peptide-derived nanoformulations in atherosclerosis: present status and future directions
inferred← citeshttps://doi.org/10.1080/21645515.2024.2365500openalex-snapshot
A bibliometric analysis of vaccination against atherosclerosis
inferred← citeshttps://doi.org/10.1093/bib/bbae616openalex-snapshot
miCGR: interpretable deep neural network for predicting both site-level and gene-level functional targets of microRNA
inferred← citeshttps://doi.org/10.1093/cvr/cvad041openalex-snapshot
Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function
inferred← citeshttps://doi.org/10.1093/eurjpc/zwae044openalex-snapshot
Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study
inferred← citeshttps://doi.org/10.1096/fj.202300248ropenalex-snapshot
TWF1 induces autophagy and accelerates malignant phenotype in lung adenocarcinoma via inhibiting the cAMP signaling pathway
inferred← citeshttps://doi.org/10.1111/apha.14272openalex-snapshot
The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism
inferred← citeshttps://doi.org/10.1134/s0022093024030116openalex-snapshot
The Synergistic Trio of Metabolic Master Regulators Sustaining a Vicious Circle of Pathological Processes in Post-Traumatic Stress Disorder
inferred← citeshttps://doi.org/10.1155/2022/4797529openalex-snapshot
Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
inferred← citeshttps://doi.org/10.1155/2024/8649365openalex-snapshot
Laminaria japonica Aresch‐Derived Fucoidan Ameliorates Hyperlipidemia by Upregulating LXRs and Suppressing SREBPs
inferred← citeshttps://doi.org/10.1155/adpp/5543717openalex-snapshot
Antiplatelet Effects of a Combination of Sappan Wood (Caesalpinia sappan L.) and Red Ginger (Zingiber officinale var. Rubrum) Extracts in a High‐Fat Diet‐Induced Rat Model
inferred← citeshttps://doi.org/10.1159/000543463openalex-snapshot
Role of Bailout Gene-Silencing Therapy in Plaque Lipid Reduction: Intravascular Imaging Study
inferred← citeshttps://doi.org/10.1161/circulationaha.121.056491openalex-snapshot
Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis
inferred← citeshttps://doi.org/10.1186/s12934-024-02355-8openalex-snapshot
RETRACTED ARTICLE: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
inferred← citeshttps://doi.org/10.1186/s12944-024-02151-8openalex-snapshot
Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers
inferred← citeshttps://doi.org/10.1186/s12944-024-02311-wopenalex-snapshot
Association between lipid-lowering agents with intervertebral disc degeneration, sciatica and low back pain: a drug-targeted mendelian randomized study and cross-sectional observation
inferred← citeshttps://doi.org/10.1186/s12944-025-02831-zopenalex-snapshot
High circulating PCSK9 concentration is associated with increased and sex-specific risks of metabolic disease, diabetes mellitus, MASLD, and long-term mortality in a Taiwanese population
inferred← citeshttps://doi.org/10.1186/s12985-024-02608-3openalex-snapshot
The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
inferred← citeshttps://doi.org/10.1186/s12986-025-01048-2openalex-snapshot
Quercetin’s regulation of glucose and lipid metabolism in gestational diabetes mellitus: role of the PCSK9/LDLR axis
inferred← citeshttps://doi.org/10.1186/s13046-022-02584-yopenalex-snapshot
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
inferred← citeshttps://doi.org/10.1186/s13098-025-01682-zopenalex-snapshot
The use of statins are associated with an increased risk of new-onset diabetes in patients with hypertension and obstructive sleep apnoea, a longitudinal study
inferred← citeshttps://doi.org/10.1186/s40001-025-02937-1openalex-snapshot
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
inferred← citeshttps://doi.org/10.1186/s40364-024-00712-8openalex-snapshot
PCSK9 in T-cell function and the immune response
inferred← citeshttps://doi.org/10.1186/s43088-025-00694-yopenalex-snapshot
PCSK9 molecular bridge between hyperlipidemia and vascular inflammation: novel insights into PCSK9-centered pathways in atherosclerosis: a comprehensive review
inferred← citeshttps://doi.org/10.12677/acm.2022.1281061openalex-snapshot
Research Progress of Inclisiran
inferred← citeshttps://doi.org/10.12677/acm.2023.13102195openalex-snapshot
Application of PCSK9 Inhibitor in Carotid Stenosis
inferred← citeshttps://doi.org/10.12677/acm.2025.15113213openalex-snapshot
Cardiovascular Protective Effects of PCSK9 Inhibitors and Research Progress in Their Application for Heart Failure Treatment
inferred← citeshttps://doi.org/10.12677/acm.2026.161286openalex-snapshot
Overview of the Study of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.12677/acm.2026.162549openalex-snapshot
The Effect and Mechanism of Lipid-Lowering Drugs on the Regression of Atherosclerotic Plaques
inferred← citeshttps://doi.org/10.12677/jcpm.2026.51069openalex-snapshot
The Relationship between PCSK9 and the Occurrence of Atherosclerosis in Patients with Systemic Lupus Erythematosus
inferred← citeshttps://doi.org/10.12775/jehs.2023.27.01.001openalex-snapshot
Inclisiran - hope in the fight against dyslipidemia
inferred← citeshttps://doi.org/10.1371/journal.pone.0346073openalex-snapshot
Identification of flavonoids from natural products against hyperlipidaemia through computational approaches
inferred← citeshttps://doi.org/10.1515/tjb-2023-0283openalex-snapshot
Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea
inferred← citeshttps://doi.org/10.15825/1995-1191-2025-4-158-172openalex-snapshot
Dyslipidemia and lipid-lowering therapy in patients on renal replacement therapy: a literature review
inferred← citeshttps://doi.org/10.18502/ijph.v52i5.12707openalex-snapshot
Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis
inferred← citeshttps://doi.org/10.18632/aging.205268openalex-snapshot
Meteorin-like protein elevation post-exercise improved vascular inflammation among coronary artery disease patients by downregulating NLRP3 inflammasome activity
inferred← citeshttps://doi.org/10.21037/atm-22-870openalex-snapshot
Association of PCSK9 levels and genetic polymorphisms with stroke recurrence and functional outcome after acute ischemic stroke
inferred← citeshttps://doi.org/10.21101/cejph.a7844openalex-snapshot
Polymorphisms rs562556 and rs2479409 of the PCSK9 gene associated with obesity and cardiovascular disease
inferred← citeshttps://doi.org/10.21123/bsj.2023.7696openalex-snapshot
Gene Expression and Methylation Levels of PCSK9 Gene in Iraqi Patients with Coronary Artery Disease
inferred← citeshttps://doi.org/10.2147/ijgm.s454633openalex-snapshot
Predictive Value of Plasma PCSK9 Levels for Degree of Atherosclerosis and Major Adverse Cardiovascular and Cerebrovascular Events in Older Adult Patients with Non-Alcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.2174/0109298673262124231102042914openalex-snapshot
The Link between miRNAs and PCKS9 in Atherosclerosis
inferred← citeshttps://doi.org/10.2174/0115672026332171240624100802openalex-snapshot
Effects of PCSK9 Inhibitors on Early Neurologic Deterioration in Patients with Acute Non-Cardioembolism without Hemorrhagic Transformation After Intravenous Thrombolysis
inferred← citeshttps://doi.org/10.2174/011573403x357542250526072430openalex-snapshot
Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.2174/1381612829666230412105238openalex-snapshot
PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.2174/1871529x23666230810094738openalex-snapshot
Analysis of Adherence to anti-PCSK9 Antibody Therapy among Patients from Italy
inferred← citeshttps://doi.org/10.22490/24629448.8196openalex-snapshot
Genética del metabolismo lipídico en la biología del desarrollo de la aterosclerosis
inferred← citeshttps://doi.org/10.23880/ijbp-16000241openalex-snapshot
Biochemical and Pathological Parameters Pertaining to Cardiovascular Disorders
inferred← citeshttps://doi.org/10.31857/s0869813924050044openalex-snapshot
Synergic Trio of Metabolic Regulators Supporting the Vicious Circle of Pathological Processes in Post-Traumatic Stress Disorder
inferred← citeshttps://doi.org/10.3233/ch-242172openalex-snapshot
RETRACTED: PCSK9 induces endothelial cell autophagy by regulating the PI3K/ATK pathway in atherosclerotic coronary heart disease
inferred← citeshttps://doi.org/10.3389/fcvm.2021.746989openalex-snapshot
Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
inferred← citeshttps://doi.org/10.3389/fcvm.2022.939972openalex-snapshot
Identification of hub biomarkers of myocardial infarction by single-cell sequencing, bioinformatics, and machine learning
inferred← citeshttps://doi.org/10.3389/fcvm.2023.1117143openalex-snapshot
Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
inferred← citeshttps://doi.org/10.3389/fcvm.2023.1191303openalex-snapshot
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
inferred← citeshttps://doi.org/10.3389/fcvm.2024.1415668openalex-snapshot
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis
inferred← citeshttps://doi.org/10.3389/fcvm.2025.1652933openalex-snapshot
Innovative molecular intervention and precision therapy for atherosclerosis
inferred← citeshttps://doi.org/10.3389/fimmu.2022.947756openalex-snapshot
Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1126823openalex-snapshot
Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
inferred← citeshttps://doi.org/10.3389/fmed.2025.1521344openalex-snapshot
Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention
inferred← citeshttps://doi.org/10.3389/fphar.2023.1260921openalex-snapshot
Inclisiran: a new generation of lipid-lowering siRNA therapeutic
inferred← citeshttps://doi.org/10.3389/fphar.2026.1800502openalex-snapshot
A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries
inferred← citeshttps://doi.org/10.3390/biomedicines11020503openalex-snapshot
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
inferred← citeshttps://doi.org/10.3390/biomedicines13122843openalex-snapshot
PCSK9 Promotes Platelet Activation and NET Formation, Aggravating Pulmonary Microthrombosis in Sepsis-Induced Lung Injury
inferred← citeshttps://doi.org/10.3390/biomedicines9070793openalex-snapshot
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
inferred← citeshttps://doi.org/10.3390/cells12121648openalex-snapshot
A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
inferred← citeshttps://doi.org/10.3390/cells12192407openalex-snapshot
An Overview of the Role of Furin in Type 2 Diabetes
inferred← citeshttps://doi.org/10.3390/diseases11040145openalex-snapshot
Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease
inferred← citeshttps://doi.org/10.3390/genes12081168openalex-snapshot
Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands
inferred← citeshttps://doi.org/10.3390/genes16091113openalex-snapshot
Effects of the PCSK9 C378W Mutation on PCSK9 Levels and Lipid Profiles in Taiwanese Individuals: A Loss-of-Function Mutation with Potential Cardiovascular Benefits
inferred← citeshttps://doi.org/10.3390/ijerph191912878openalex-snapshot
A Systematic Review on Attenuation of PCSK9 in Relation to Atherogenesis Biomarkers Associated with Natural Products or Plant Bioactive Compounds in In Vitro Studies: A Critique on the Quality and Imprecision of Studies
inferred← citeshttps://doi.org/10.3390/ijms222313001openalex-snapshot
Ultrastructural Study of Platelet Behavior and Interrelationship in Sprouting and Intussusceptive Angiogenesis during Arterial Intimal Thickening Formation
inferred← citeshttps://doi.org/10.3390/ijms231810418openalex-snapshot
Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
inferred← citeshttps://doi.org/10.3390/ijms232213842openalex-snapshot
Fat Checking: Emerging Role of Lipids in Metabolism and Disease
inferred← citeshttps://doi.org/10.3390/ijms24031966openalex-snapshot
PCSK9 as an Atherothrombotic Risk Factor
inferred← citeshttps://doi.org/10.3390/ijms24108869openalex-snapshot
Caveolin-1 and Atherosclerosis: Regulation of LDLs Fate in Endothelial Cells
inferred← citeshttps://doi.org/10.3390/ijms241411739openalex-snapshot
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
inferred← citeshttps://doi.org/10.3390/ijms241914668openalex-snapshot
Exploring PCSK9 Genetic Impact on Lipoprotein(a) via Dual Approaches: Association and Mendelian Randomization
inferred← citeshttps://doi.org/10.3390/ijms26031003openalex-snapshot
PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose
inferred← citeshttps://doi.org/10.3390/ijms26031026openalex-snapshot
Novel RNA-Based Therapies in the Management of Dyslipidemias
inferred← citeshttps://doi.org/10.3390/jcdd12090355openalex-snapshot
The Effects of Inclisiran on the Subclinical Prothrombotic and Platelet Activation Markers in Patients at High Cardiovascular Risk
inferred← citeshttps://doi.org/10.3390/jcdd12100384openalex-snapshot
Metabolic Reprogramming and Cell Interaction in Atherosclerosis: From Molecular Mechanisms to Therapeutic Strategies
inferred← citeshttps://doi.org/10.3390/jcm11113247openalex-snapshot
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients
inferred← citeshttps://doi.org/10.3390/jcm11133625openalex-snapshot
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
inferred← citeshttps://doi.org/10.3390/jcm12196225openalex-snapshot
Multi-Omic Candidate Screening for Markers of Severe Clinical Courses of COVID-19
inferred← citeshttps://doi.org/10.3390/jpm13071077openalex-snapshot
The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis
inferred← citeshttps://doi.org/10.3390/life12020190openalex-snapshot
PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
inferred← citeshttps://doi.org/10.3390/life12101531openalex-snapshot
Increased Carotid Intima-Media Thickness in Asymptomatic Individuals Is Associated with the PCSK9 (rs2149041) Gene Polymorphism in the Mexican Mestizo Population: Results of the GEA Cohort
inferred← citeshttps://doi.org/10.3390/metabo12030226openalex-snapshot
Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
inferred← citeshttps://doi.org/10.3390/molecules30173582openalex-snapshot
Naturally Occurring PCSK9 Inhibitors: An Updated Review
inferred← citeshttps://doi.org/10.3390/nu15204463openalex-snapshot
High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study
inferred← citeshttps://doi.org/10.3390/nu17091411openalex-snapshot
Genetic Variants, Bioactive Compounds, and PCSK9 Inhibitors in Hyper-LDL-Cholesterolemia: A GWAS and In Silico Study on Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.3390/nu17091445openalex-snapshot
(−)-Oleuropein as a Novel Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence Suppressor via Targeting PCSK9-LDLR Axis
inferred← citeshttps://doi.org/10.3390/ph16091197openalex-snapshot
The Anti-Thrombotic Effects of PCSK9 Inhibitors
inferred← citeshttps://doi.org/10.3390/pharmaceutics15020323openalex-snapshot
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
inferred← citeshttps://doi.org/10.3390/pharmaceutics17020238openalex-snapshot
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases
inferred← citeshttps://doi.org/10.3390/pharmacy13050125openalex-snapshot
Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence
inferred← citeshttps://doi.org/10.3844/ojbsci.2024.208.218openalex-snapshot
Overview of the Most Popular Currently Used Murine Models of Atherosclerosis
inferred← citeshttps://doi.org/10.3892/etm.2025.12796openalex-snapshot
Dendrobium nobile Lindl. alkaloids improve lipid metabolism by increasing LDL uptake through regulation of the LXRα/IDOL/LDLR pathway and inhibition of PCSK9 expression in HepG2 cells
inferred← citeshttps://doi.org/10.3892/ijmm.2024.5381openalex-snapshot
Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review)
inferred← citeshttps://doi.org/10.4103/jpdtsm.jpdtsm_112_24openalex-snapshot
A Systematic Review with Network Meta-analysis on Atherosclerosis Vaccine Based on Nonhuman Primate Model
inferred← citeshttps://doi.org/10.4103/nrr.nrr-d-24-01523openalex-snapshot
Lipid metabolism, microglia, and stroke
inferred← citeshttps://doi.org/10.4103/tcmj.tcmj_46_24openalex-snapshot
Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
inferred← citeshttps://doi.org/10.4236/ajmb.2025.151009openalex-snapshot
The Impact of PCSK9 on Risk Factors for Ischemic Stroke and Potential Mechanisms
inferred← citeshttps://doi.org/10.4244/eij-e-22-00032openalex-snapshot
In search of the pleiotropic effects of PCSK9 inhibitors
inferred← citeshttps://doi.org/10.58871/conimaps24.c24openalex-snapshot
INIBIDORES DA PCSK9 NO TRATAMENTO DA HIPERCOLESTEROLEMIA: UMA REVISÃO INTEGRATIVA DA LITERATURA
inferred← citeshttps://doi.org/10.5937/medi0-55356openalex-snapshot
Treatment of dyslipidemia: PCSK-9 in focus
inferred← citeshttps://doi.org/10.6084/m9.figshare.26697524openalex-snapshot
Additional file 1 of Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
inferred← citeshttps://doi.org/10.7150/thno.83914openalex-snapshot
PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
inferred← citeshttps://doi.org/10.7759/cureus.29140openalex-snapshot
A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease
inferred← citeshttps://doi.org/10.7759/cureus.69918openalex-snapshot
Inclisiran: A Systematic Review Exploring the Revolutionary Approach of Twice-Yearly Dosing Regimen in the Treatment of Hypercholesterolemia
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.